Novel Murine Pancreatic Tumor Model Demonstrates Immunotherapeutic Control of Tumor Progression by a Toxoplasma gondii Protein
Susan N. Payne, Philip B. Emmerich, Nicole M. Davis, Dustin A. Deming, Laura J. Knoll
Abstract
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related death in the United States, with few effective treatments available and only 10% of those diagnosed surviving 5 years. Although immunotherapeutics is a growing field of study in cancer biology, there has been little progress in its use for the treatment of pancreatic cancer.
Topics & Concepts
Immune systemPancreatic cancerBiologyToxoplasma gondiiCancer researchTumor progressionImmunotherapyPancreatic tumorTumor microenvironmentCancerAdenocarcinomaImmunologyAntigenMetastasisCancer cellDendritic cellSyngenicPancreasTumor antigenImmunoeditingPancreatic diseaseImmunogenic cell deathAntibodyInterferon gammaToxoplasma gondii Research StudiesCancer Research and TreatmentsAmoebic Infections and Treatments